Does the media prefer VRTX or AMZN?

In the previous week, Amazon.com had 265 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 295 mentions for Amazon.com and 30 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.21 beat Amazon.com's score of 0.89 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 21 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amazon.com 185 Very Positive mention(s) 38 Positive mention(s) 34 Neutral mention(s) 21 Negative mention(s) 9 Very Negative mention(s) Positive

Does the media prefer VRTX or AXSM?

In the previous week, Vertex Pharmaceuticals had 21 more articles in the media than Axsome Therapeutics. MarketBeat recorded 30 mentions for Vertex Pharmaceuticals and 9 mentions for Axsome Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 1.21 beat Axsome Therapeutics' score of 0.67 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 21 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor CRSP or VRTX?

In the previous week, Vertex Pharmaceuticals had 24 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 30 mentions for Vertex Pharmaceuticals and 6 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 1.33 beat Vertex Pharmaceuticals' score of 1.21 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vertex Pharmaceuticals 21 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EDIT or VRTX?

In the previous week, Editas Medicine had 5 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 35 mentions for Editas Medicine and 30 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.21 beat Editas Medicine's score of 0.75 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Vertex Pharmaceuticals 21 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, GOOG or VRTX?

Alphabet has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Alphabet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alphabet $402.84B 11.32 $132.17B $13.11 28.71 Vertex Pharmaceuticals $12.00B 9.46 $3.95B $16.86 26.54

Does the media favor GOOG or VRTX?

In the previous week, Alphabet had 150 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 180 mentions for Alphabet and 30 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.21 beat Alphabet's score of 0.81 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alphabet 110 Very Positive mention(s) 20 Positive mention(s) 21 Neutral mention(s) 24 Negative mention(s) 4 Very Negative mention(s) Positive Vertex Pharmaceuticals 21 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Vertex Pharmaceuticals (VRTX) Competitors

$447.54 -0.43 (-0.10%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$446.83 -0.71 (-0.16%)

As of 05/29/2026 07:52 PM Eastern

Compare

VRTX vs. AMZN, AXSM, CRSP, EDIT, and GOOG

Should you buy Vertex Pharmaceuticals stock or one of its competitors? MarketBeat compares Vertex Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vertex Pharmaceuticals include Amazon.com (AMZN), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Alphabet (GOOG).

How does Vertex Pharmaceuticals compare to Amazon.com?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Amazon.com (NASDAQ:AMZN) are related large-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Amazon.com had 265 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 295 mentions for Amazon.com and 30 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.21 beat Amazon.com's score of 0.89 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	21 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Amazon.com	185 Very Positive mention(s)	38 Positive mention(s)	34 Neutral mention(s)	21 Negative mention(s)	9 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has a net margin of 35.51% compared to Amazon.com's net margin of 12.22%. Vertex Pharmaceuticals' return on equity of 23.86% beat Amazon.com's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
Amazon.com	12.22%	19.92%	9.86%

Vertex Pharmaceuticals currently has a consensus target price of $555.91, indicating a potential upside of 24.22%. Amazon.com has a consensus target price of $312.83, indicating a potential upside of 15.59%. Given Vertex Pharmaceuticals' higher possible upside, equities research analysts plainly believe Vertex Pharmaceuticals is more favorable than Amazon.com.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88
Amazon.com	0 Sell rating(s)	3 Hold rating(s)	57 Buy rating(s)	0 Strong Buy rating(s)	2.95

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 72.2% of Amazon.com shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 8.9% of Amazon.com shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Amazon.com has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amazon.com, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	9.46	$3.95B	$16.86	26.54
Amazon.com	$716.92B	4.06	$77.67B	$8.36	32.37

Vertex Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Amazon.com has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

Summary

Vertex Pharmaceuticals and Amazon.com tied by winning 8 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Vertex Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	9.46	$3.95B	$16.86	26.54
Axsome Therapeutics	$638.50M	18.90	-$183.17M	-$3.73	N/A

Vertex Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

In the previous week, Vertex Pharmaceuticals had 21 more articles in the media than Axsome Therapeutics. MarketBeat recorded 30 mentions for Vertex Pharmaceuticals and 9 mentions for Axsome Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 1.21 beat Axsome Therapeutics' score of 0.67 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	21 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Vertex Pharmaceuticals presently has a consensus price target of $555.91, indicating a potential upside of 24.22%. Axsome Therapeutics has a consensus price target of $251.26, indicating a potential upside of 7.16%. Given Vertex Pharmaceuticals' higher possible upside, equities research analysts clearly believe Vertex Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Vertex Pharmaceuticals has a net margin of 35.51% compared to Axsome Therapeutics' net margin of -26.59%. Vertex Pharmaceuticals' return on equity of 23.86% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Axsome Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

CRISPR Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

CRISPR Therapeutics presently has a consensus target price of $65.47, indicating a potential upside of 16.71%. Vertex Pharmaceuticals has a consensus target price of $555.91, indicating a potential upside of 24.22%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88

Vertex Pharmaceuticals has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,541.44	-$581.60M	-$6.22	N/A
Vertex Pharmaceuticals	$12.00B	9.46	$3.95B	$16.86	26.54

In the previous week, Vertex Pharmaceuticals had 24 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 30 mentions for Vertex Pharmaceuticals and 6 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 1.33 beat Vertex Pharmaceuticals' score of 1.21 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	21 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has a net margin of 35.51% compared to CRISPR Therapeutics' net margin of -13,856.54%. Vertex Pharmaceuticals' return on equity of 23.86% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats CRISPR Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

Editas Medicine has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

Editas Medicine currently has a consensus target price of $5.40, indicating a potential upside of 56.07%. Vertex Pharmaceuticals has a consensus target price of $555.91, indicating a potential upside of 24.22%. Given Editas Medicine's higher probable upside, equities research analysts clearly believe Editas Medicine is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Editas Medicine had 5 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 35 mentions for Editas Medicine and 30 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.21 beat Editas Medicine's score of 0.75 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	21 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	8.36	-$160.06M	-$1.23	N/A
Vertex Pharmaceuticals	$12.00B	9.46	$3.95B	$16.86	26.54

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vertex Pharmaceuticals has a net margin of 35.51% compared to Editas Medicine's net margin of -281.59%. Vertex Pharmaceuticals' return on equity of 23.86% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

Summary

Vertex Pharmaceuticals beats Editas Medicine on 11 of the 15 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Alphabet?

Alphabet (NASDAQ:GOOG) and Vertex Pharmaceuticals (NASDAQ:VRTX) are related large-cap companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Alphabet has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Alphabet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alphabet	$402.84B	11.32	$132.17B	$13.11	28.71
Vertex Pharmaceuticals	$12.00B	9.46	$3.95B	$16.86	26.54

Alphabet presently has a consensus target price of $372.65, indicating a potential downside of 1.01%. Vertex Pharmaceuticals has a consensus target price of $555.91, indicating a potential upside of 24.22%. Given Vertex Pharmaceuticals' higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Alphabet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alphabet	0 Sell rating(s)	4 Hold rating(s)	28 Buy rating(s)	6 Strong Buy rating(s)	3.05
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88

27.3% of Alphabet shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 13.0% of Alphabet shares are held by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Alphabet had 150 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 180 mentions for Alphabet and 30 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.21 beat Alphabet's score of 0.81 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alphabet	110 Very Positive mention(s)	20 Positive mention(s)	21 Neutral mention(s)	24 Negative mention(s)	4 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	21 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Alphabet has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Alphabet has a net margin of 37.92% compared to Vertex Pharmaceuticals' net margin of 35.51%. Alphabet's return on equity of 38.99% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alphabet	37.92%	38.99%	27.41%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

Summary

Alphabet beats Vertex Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

Get Vertex Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRTX vs. The Competition

Export

Metric	Vertex Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$113.59B	$3.41B	$5.96B	$12.56B
Dividend Yield	N/A	2.29%	2.69%	5.31%
P/E Ratio	26.54	19.04	21.41	26.27
Price / Sales	9.46	342.04	626.55	142.41
Price / Cash	25.46	121.88	43.22	56.84
Price / Book	6.08	7.12	10.55	7.30
Net Income	$3.95B	$24.20M	$3.56B	$337.27M
7 Day Performance	3.00%	4.11%	2.85%	3.58%
1 Month Performance	4.72%	6.66%	4.59%	5.71%
1 Year Performance	1.02%	66.00%	37.62%	39.70%

Vertex Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRTX Vertex Pharmaceuticals	4.5414 of 5 stars	$447.54 -0.1%	$555.91 +24.2%	+1.0%	$113.59B	$12.00B	26.54	6,400	Positive News Analyst Forecast
AMZN Amazon.com	4.5807 of 5 stars	$266.32 flat	$312.66 +17.4%	+32.7%	$2.86T	$716.92B	31.86	1,576,000	Trending News Analyst Forecast Insider Trade
AXSM Axsome Therapeutics	2.4089 of 5 stars	$235.97 flat	$251.26 +6.5%	+123.5%	$12.14B	$638.50M	N/A	380
CRSP CRISPR Therapeutics	2.4549 of 5 stars	$50.36 flat	$65.47 +30.0%	+55.6%	$4.86B	$3.51M	N/A	460	Positive News Analyst Forecast
EDIT Editas Medicine	3.4014 of 5 stars	$2.76 flat	$5.40 +95.7%	+99.4%	$270.23M	$40.52M	N/A	230	Trending News Analyst Forecast Options Volume Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRTX) was last updated on 5/31/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, EDIT, and GOOG

How does Vertex Pharmaceuticals compare to Amazon.com?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to Editas Medicine?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, EDIT, and GOOG

How does Vertex Pharmaceuticals compare to Amazon.com?

Does the media prefer VRTX or AMZN?

Is VRTX or AMZN more profitable?

Do analysts recommend VRTX or AMZN?

Do institutionals and insiders believe in VRTX or AMZN?

Which has preferable valuation & earnings, VRTX or AMZN?

Which has more risk & volatility, VRTX or AMZN?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Which has stronger earnings and valuation, VRTX or AXSM?

Which has more volatility & risk, VRTX or AXSM?

Does the media prefer VRTX or AXSM?

Do analysts recommend VRTX or AXSM?

Is VRTX or AXSM more profitable?

Do institutionals & insiders believe in VRTX or AXSM?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Which has more volatility & risk, CRSP or VRTX?

Do analysts rate CRSP or VRTX?

Which has higher earnings and valuation, CRSP or VRTX?

Does the media favor CRSP or VRTX?

Is CRSP or VRTX more profitable?

Do insiders & institutionals have more ownership in CRSP or VRTX?

Summary

How does Vertex Pharmaceuticals compare to Editas Medicine?

Which has more risk & volatility, EDIT or VRTX?

Do analysts prefer EDIT or VRTX?

Does the media refer more to EDIT or VRTX?

Which has stronger earnings & valuation, EDIT or VRTX?

Do insiders and institutionals believe in EDIT or VRTX?

Is EDIT or VRTX more profitable?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Which has preferable earnings and valuation, GOOG or VRTX?

Do analysts prefer GOOG or VRTX?

Do insiders & institutionals have more ownership in GOOG or VRTX?

Does the media favor GOOG or VRTX?

Which has more risk and volatility, GOOG or VRTX?

Is GOOG or VRTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools